Xenoport Inc (XNPT) 4.20 $XNPT
XenoPort Has Returned 9.3% Since SmarTrend Recommendation (XNPT)
Comtex SmarTrend(R) - Fri Mar 28, 10:05AM CDT
SmarTrend identified a Downtrend for XenoPort (NASDAQ:XNPT) on February 3rd, 2014 at $5.73. In approximately 2 months, XenoPort has returned 9.34% as of today's recent price of $5.19.
XenoPort Earnings In Retrospect: Down 0.3% in the Last 18 Days (XNPT)
Comtex SmarTrend(R) - Mon Mar 10, 7:55AM CDT
When XenoPort (NASDAQ:XNPT) reported earnings 18 days ago on February 20th, 2014, analysts, on average, expected the company to report a loss of $0.48 on sales of $3.8 million. XenoPort actually reported a loss of $0.40 per share on sales of $2.9 million, beating EPS estimates by $0.08 and missing revenue estimates by $0.9 million. Shares of XenoPort have slipped from $5.89 to $5.87, representing a loss of 0.3%, since the company reported earnings 18 days ago.
ESI to Present at Two March Investor Conferences
Business Wire - Tue Mar 04, 7:55AM CST
Electro Scientific Industries, Inc. (NASDAQ: ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced it will be participating at two upcoming investor conferences, including:
XenoPort to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Mon Feb 24, 9:00AM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2014 Cowen and Company 34th Annual Health Care Conference. The live presentation will occur at 7:40 a.m. Pacific Time (10:40 a.m. Eastern Time) on Wednesday, March 5, 2014. A replay of the presentation will also be available.
XenoPort's 4Q Loss Narrower-Than-Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 10:22AM CST
XenoPort's loss narrows in fourth quarter of 2013.
XenoPort Reports Fourth Quarter and Year-End 2013 Financial Results
Business Wire - Thu Feb 20, 3:05PM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that resulted from a non-cash gain from XenoPort's litigation settlement with Glaxo Group Limited (GSK) in the fourth quarter of 2012. At December 31, 2013, XenoPort had cash and cash equivalents and short-term investments of $58.7 million.
UPS Honors New York Drivers for 25 Years of Safe Driving
Business Wire - Wed Feb 19, 9:00AM CST
UPS (NYSE:UPS) today announced 46 elite drivers from New York are among 1,519 newly inducted worldwide into the Circle of Honor, an honorary organization for UPS drivers who have achieved 25 or more years of accident-free driving.
Can a New Indication for Lyrica Help Results at Pfizer?
Eileen Rojas, The Motley Fool - Motley Fool - Tue Feb 18, 4:16PM CST
As revenue at Pfizer continues to decline, some relief may come in the form of a new indication for Lyrica, one of the company's top-selling drugs, to treat restless legs syndrome, or RLS. Lyrica was a top seller during 2013 Lyrica was a top...
XenoPort to Present at the RBC Capital Markets' Global Healthcare Conference
Business Wire - Tue Feb 18, 12:06PM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the RBC Capital Markets' Global Healthcare Conference. The live presentation will occur at 11:35 a.m. Pacific Time (2:35 p.m. Eastern Time) on Tuesday, February 25, 2014. A replay of the presentation will also be available.
RLS/WED Survey of Patients' Spouses and Partners Reveals Their Concern of Disease-Related Burdens
Business Wire - Thu Feb 13, 7:30AM CST
The Willis-Ekbom Disease (WED) Foundation and XenoPort, Inc. (Nasdaq:XNPT) announced today the second phase of results from the "Patient Odyssey" survey, which reveals how Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) may affect the lifestyles and emotional health of patients and their spouses/partners. The survey findings add another important layer of information to the current body of knowledge on RLS/WED. Moreover, the results from the survey showed that spouses/partners understand the impact of RLS/WED, as they are affected by the disease as well. The full survey results are available on the WED Foundation website (www.Willis-Ekbom.org).
XenoPort to Release Fourth Quarter and Year-End Financial Results on February 20, 2014
Business Wire - Wed Feb 12, 7:48PM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its fourth quarter financial results on February 20, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.
XenoPort Appoints Richard Kim, M.D., as Chief Medical Officer
Business Wire - Wed Jan 29, 7:30AM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today that Richard Kim, M.D., has been appointed senior vice president, clinical development and medical affairs, and chief medical officer. Dr. Kim joined XenoPort in July 2013 as vice president of medical affairs, supporting XenoPort's launch of HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets. Dr. Kim has more than a decade of experience in both clinical development and medical affairs, most recently as vice president of clinical development and head of the multiple sclerosis therapeutic area at Elan Pharmaceuticals, Inc.
XenoPort Inc prices public offering at USD6.00 per share
M2 - Fri Jan 24, 4:07AM CST
Biopharmaceutical company XenoPort Inc (NasdaqGS :XNPT) said on Friday that it has priced a registered public offering of 12,000,000 shares of its common stock.
XenoPort Announces Pricing of Public Offering of Common Stock
Business Wire - Thu Jan 23, 10:00PM CST
XenoPort, Inc. (NASDAQ: XNPT) announced today the pricing of an underwritten registered public offering of 12,000,000 shares of its common stock at a price to the public of $6.00 per share. The size of the offering was increased from the 10,000,000 shares previously announced. XenoPort has also granted to the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of its common stock. All of the shares in the offering are being offered by XenoPort. The offering is expected to close on or about January 29, 2014, subject to customary closing conditions.
XenoPort Inc to offer 10m common shares in public offering
M2 - Wed Jan 22, 4:02AM CST
Biopharmaceutical company XenoPort Inc (NasdaqGS:XNPT) said on Tuesday that it proposes to offer and sell 10,000,000 shares of its common stock in an underwritten public offering.
XenoPort Announces Proposed Public Offering of Common Stock
Business Wire - Tue Jan 21, 5:00AM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today that it intends to offer and sell 10,000,000 shares of its common stock, subject to market and other conditions, in an underwritten public offering. XenoPort also intends to grant the underwriters a 30-day option to purchase up to a maximum of 1,500,000 additional shares of common stock. All of the shares in the proposed public offering are to be sold by XenoPort.
Pipeline Update from XenoPort - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 5:50PM CST
XenoPort provides update on its pipeline
Updates on Clinical Trial Enrollment, Product Development Updates, Clinical Collaboration, and Preliminary Sales Report - Research Report on Raptor, Synageva, XenoPort, Portola, and Zogenix
PR Newswire - Thu Jan 16, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Synageva BioPharma Corporation (NASDAQ: GEVA), XenoPort, Inc. (NASDAQ: XNPT), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), and Zogenix, Inc. (NASDAQ: ZGNX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
XenoPort Provides Updates on XP23829 Development and HORIZANT Performance Highlights
Business Wire - Sun Jan 12, 11:59AM CST
XenoPort (NASDAQ:XNPT) today reported an update on XP23289 development, including feedback from the U.S. Food and Drug Administration (FDA) on the potential development plans, and XenoPort's progress on commercializing HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets.
Can the Rally in XenoPort, Inc. (XNPT) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 8:01AM CST
Can the Rally in XenoPort, Inc. (XNPT) Shares Continue?
XenoPort Has Returned 9.3% Since SmarTrend Recommendation (XNPT)
Comtex SmarTrend(R) - Fri Mar 28, 10:05AM CDT
SmarTrend identified a Downtrend for XenoPort (NASDAQ:XNPT) on February 3rd, 2014 at $5.73. In approximately 2 months, XenoPort has returned 9.34% as of today's recent price of $5.19.
XenoPort Earnings In Retrospect: Down 0.3% in the Last 18 Days (XNPT)
Comtex SmarTrend(R) - Mon Mar 10, 7:55AM CDT
When XenoPort (NASDAQ:XNPT) reported earnings 18 days ago on February 20th, 2014, analysts, on average, expected the company to report a loss of $0.48 on sales of $3.8 million. XenoPort actually reported a loss of $0.40 per share on sales of $2.9 million, beating EPS estimates by $0.08 and missing revenue estimates by $0.9 million. Shares of XenoPort have slipped from $5.89 to $5.87, representing a loss of 0.3%, since the company reported earnings 18 days ago.
ESI to Present at Two March Investor Conferences
Business Wire - Tue Mar 04, 7:55AM CST
Electro Scientific Industries, Inc. (NASDAQ: ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced it will be participating at two upcoming investor conferences, including:
XenoPort to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Mon Feb 24, 9:00AM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2014 Cowen and Company 34th Annual Health Care Conference. The live presentation will occur at 7:40 a.m. Pacific Time (10:40 a.m. Eastern Time) on Wednesday, March 5, 2014. A replay of the presentation will also be available.
XenoPort's 4Q Loss Narrower-Than-Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 10:22AM CST
XenoPort's loss narrows in fourth quarter of 2013.
XenoPort Reports Fourth Quarter and Year-End 2013 Financial Results
Business Wire - Thu Feb 20, 3:05PM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that resulted from a non-cash gain from XenoPort's litigation settlement with Glaxo Group Limited (GSK) in the fourth quarter of 2012. At December 31, 2013, XenoPort had cash and cash equivalents and short-term investments of $58.7 million.
UPS Honors New York Drivers for 25 Years of Safe Driving
Business Wire - Wed Feb 19, 9:00AM CST
UPS (NYSE:UPS) today announced 46 elite drivers from New York are among 1,519 newly inducted worldwide into the Circle of Honor, an honorary organization for UPS drivers who have achieved 25 or more years of accident-free driving.
Can a New Indication for Lyrica Help Results at Pfizer?
Eileen Rojas, The Motley Fool - Motley Fool - Tue Feb 18, 4:16PM CST
As revenue at Pfizer continues to decline, some relief may come in the form of a new indication for Lyrica, one of the company's top-selling drugs, to treat restless legs syndrome, or RLS. Lyrica was a top seller during 2013 Lyrica was a top...
XenoPort to Present at the RBC Capital Markets' Global Healthcare Conference
Business Wire - Tue Feb 18, 12:06PM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the RBC Capital Markets' Global Healthcare Conference. The live presentation will occur at 11:35 a.m. Pacific Time (2:35 p.m. Eastern Time) on Tuesday, February 25, 2014. A replay of the presentation will also be available.
RLS/WED Survey of Patients' Spouses and Partners Reveals Their Concern of Disease-Related Burdens
Business Wire - Thu Feb 13, 7:30AM CST
The Willis-Ekbom Disease (WED) Foundation and XenoPort, Inc. (Nasdaq:XNPT) announced today the second phase of results from the "Patient Odyssey" survey, which reveals how Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) may affect the lifestyles and emotional health of patients and their spouses/partners. The survey findings add another important layer of information to the current body of knowledge on RLS/WED. Moreover, the results from the survey showed that spouses/partners understand the impact of RLS/WED, as they are affected by the disease as well. The full survey results are available on the WED Foundation website (www.Willis-Ekbom.org).
XenoPort to Release Fourth Quarter and Year-End Financial Results on February 20, 2014
Business Wire - Wed Feb 12, 7:48PM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its fourth quarter financial results on February 20, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.
XenoPort Appoints Richard Kim, M.D., as Chief Medical Officer
Business Wire - Wed Jan 29, 7:30AM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today that Richard Kim, M.D., has been appointed senior vice president, clinical development and medical affairs, and chief medical officer. Dr. Kim joined XenoPort in July 2013 as vice president of medical affairs, supporting XenoPort's launch of HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets. Dr. Kim has more than a decade of experience in both clinical development and medical affairs, most recently as vice president of clinical development and head of the multiple sclerosis therapeutic area at Elan Pharmaceuticals, Inc.
XenoPort Inc prices public offering at USD6.00 per share
M2 - Fri Jan 24, 4:07AM CST
Biopharmaceutical company XenoPort Inc (NasdaqGS :XNPT) said on Friday that it has priced a registered public offering of 12,000,000 shares of its common stock.
XenoPort Announces Pricing of Public Offering of Common Stock
Business Wire - Thu Jan 23, 10:00PM CST
XenoPort, Inc. (NASDAQ: XNPT) announced today the pricing of an underwritten registered public offering of 12,000,000 shares of its common stock at a price to the public of $6.00 per share. The size of the offering was increased from the 10,000,000 shares previously announced. XenoPort has also granted to the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of its common stock. All of the shares in the offering are being offered by XenoPort. The offering is expected to close on or about January 29, 2014, subject to customary closing conditions.
XenoPort Inc to offer 10m common shares in public offering
M2 - Wed Jan 22, 4:02AM CST
Biopharmaceutical company XenoPort Inc (NasdaqGS:XNPT) said on Tuesday that it proposes to offer and sell 10,000,000 shares of its common stock in an underwritten public offering.
XenoPort Announces Proposed Public Offering of Common Stock
Business Wire - Tue Jan 21, 5:00AM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today that it intends to offer and sell 10,000,000 shares of its common stock, subject to market and other conditions, in an underwritten public offering. XenoPort also intends to grant the underwriters a 30-day option to purchase up to a maximum of 1,500,000 additional shares of common stock. All of the shares in the proposed public offering are to be sold by XenoPort.
Pipeline Update from XenoPort - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 5:50PM CST
XenoPort provides update on its pipeline
Updates on Clinical Trial Enrollment, Product Development Updates, Clinical Collaboration, and Preliminary Sales Report - Research Report on Raptor, Synageva, XenoPort, Portola, and Zogenix
PR Newswire - Thu Jan 16, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Synageva BioPharma Corporation (NASDAQ: GEVA), XenoPort, Inc. (NASDAQ: XNPT), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), and Zogenix, Inc. (NASDAQ: ZGNX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
XenoPort Provides Updates on XP23829 Development and HORIZANT Performance Highlights
Business Wire - Sun Jan 12, 11:59AM CST
XenoPort (NASDAQ:XNPT) today reported an update on XP23289 development, including feedback from the U.S. Food and Drug Administration (FDA) on the potential development plans, and XenoPort's progress on commercializing HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets.
Can the Rally in XenoPort, Inc. (XNPT) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 8:01AM CST
Can the Rally in XenoPort, Inc. (XNPT) Shares Continue?
